Could a targeted drug let men skip months of hormone therapy?
NCT ID NCT07550517
First seen May 01, 2026 · Last updated May 07, 2026 · Updated 2 times
Summary
This study tests whether adding a targeted radioactive drug (177Lu-PSMA-617) to standard radiation can safely allow men with high-risk prostate cancer to take hormone therapy for only 6 months instead of the usual 24 months. The goal is to maintain cancer control while reducing side effects like hot flashes and fatigue. About 60 men will participate, and the study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK LOCALIZED PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.